Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.

Eisai & Nuvation Bio ink exclusive licensing pact for taletrectinib in Europe and additional countries outside US, China and Japan: Tokyo Thursday, January 15, 2026, 10:00 Hrs [IS ...

Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presence Next-generation BTK protein degrader APG-3288 receives IND clearance ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...

The "Cancer Antibody Drug Conjugates Global Market Report 2025" has been added to ResearchAndMarkets.com's offering.The ...

Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

Today, I live with cancer, but I don’t let it define me. I choose to define my story by courage, trust, and hope. I’ve ...

An insurance company decided that profits matter more than the life of a man who spent his career protecting this city,” said ...

ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North ...

Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...